New clinical trial sites activated in Europe for CANVAS
PRR - Prima BioMed Activates New Clinical Trial Sites in Europe for CANVAS
Prima BioMed announced that it has activated a substantial number of additional clinical trial sites in Belgium, Bulgaria, Germany, Lithuania, and Latvia. CANVAS is a phase 2/3 study of CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy. This expansion in Europe doubles the number of actively recruiting clinical trial sites for the trial, which has been ongoing at sites in Australia, Belarus, Ukraine, and the US.